U.S. patent number 3,789,118 [Application Number 05/163,498] was granted by the patent office on 1974-01-29 for medical adhesive solvent composition.
Invention is credited to Arthur B. Broerman.
United States Patent |
3,789,118 |
Broerman |
January 29, 1974 |
MEDICAL ADHESIVE SOLVENT COMPOSITION
Abstract
A solvent composition is provided which will efficiently remove
medical adhesives, particularly adhesives containing silicone
resins, from skin and simultaneously replace body oils, and prepare
the skin to receive subsequent applications of the adhesive. The
solvent composition comprises a major effective amount of a liquid
aliphatic hydrocarbon solvent fraction, preferably a C.sub.8 to
C.sub.11 aliphatic hydrocarbon fraction, a minor effective skin
conditioning amount (generally comprising at least about 2 weight
percent) of silicone fluid, and preferably, a minor effective
amount of a flash point suppressant for the liquid aliphatic
hydrocarbon fraction.
Inventors: |
Broerman; Arthur B.
(Bartlesville, OK) |
Family
ID: |
22590267 |
Appl.
No.: |
05/163,498 |
Filed: |
July 16, 1971 |
Current U.S.
Class: |
424/45; 134/42;
514/63; 134/38; 252/364 |
Current CPC
Class: |
A61K
9/0014 (20130101); A61K 47/06 (20130101) |
Current International
Class: |
A61K
47/06 (20060101); B01f 001/00 (); C23g 005/00 ();
A61k 009/00 () |
Field of
Search: |
;252/364
;424/184,78,45 |
References Cited
[Referenced By]
U.S. Patent Documents
Primary Examiner: Rose; Shep K.
Attorney, Agent or Firm: Richards, Harris & Hubbard
Claims
I claim:
1. A skin conditioning medical adhesive solvent and skin
preparation composition which consists essentially of:
a. about 2 to about 10 weight percent of liquid organosiloxane
polymer effective to replace body fats and oils leached from the
skin by solvent action:
b. about 5 to about 25 weight percent of a halogenated lower alkyl
hydrocarbon flashpoint suppressant selected from the group
consisting of trichloroethane, tetrachlorodifluoroethane,
trichloromonofluoromethane, trichlorotrifluoroethane, and mixtures
thereof; and
c. the balance of said composition which consists essentially of a
solvent of from about 30 to about 70 weight percent of a mixture of
C.sub. 8 - C.sub. 9 aliphatic hydrocarbons and from about 30 to
about 70 weight percent of a mixture of C.sub. 10 - C.sub. 11
aliphatic hydrocarbons;
said solvent not imparting deleterious results to the skin, said
composition forming a more efficient seal with silicone resin
medical adhesive between the skin and a prosthetic device or
appliance upon reapplication thereof.
2. The composition of claim 1 wherein said flashpoint suppressant
is trichloroethane.
3. The composition of claim 1 wherein said flashpoint suppressant
is trichlorotrifluoroethane.
4. A medical adhesive solvent and skin preparation composition
which consists essentially of 80 parts by weight of a solvent
constituent which includes a liquid aliphatic hydrocarbon fraction
which consists essentially of from about 30 to about 70 weight
percent of a mixture of C.sub. 8 - C.sub. 9 aliphatic hydrocarbons
and from about 30 to about 70 weight percent of a mixture of C.sub.
10 - C.sub. 11 aliphatic hydrocarbons; 18 parts by weight of a
halogenated lower alkyl hydrocarbon selected from the group
consisting of trichloroethane, tetrachlorodifluoroethane,
trichloromonofluoromethane, trichlorotrifluoroethane, and mixtures
thereof; and 2 parts by weight of a liquid organosiloxane polymer.
Description
This invention relates to solvents. In another aspect, this
invention relates to a novel medical solvent and skin preparation
composition. In still another aspect, this invention relates to a
novel method of applying and removing prosthetic devices and the
like from the skin.
Various medical prosthetic devices and body appliances are utilized
which are affixed to the human body with a medical adhesive
composition. Widely utilized body appliances include cosmetic body
appliances for covering scars resulting from severe injuries, for
example. These appliances are generally made of silicone rubber and
utilize a silicone resin medical adhesive to affix them to the body
surface. Prosthetic devices include male urinal devices which are
affixed to the body with medical adhesives.
Thus, such medical prosthetic devices and body appliances must,
when in use, be securely affixed to the skin of the patient.
However, for medicinal and hygienic reasons, such devices and
appliances must be periodically removed from the skin and then
later reapplied thereto.
Since the conventional medical adhesive compositions will
tenaceously adhere to both the prosthetic device, or body appliance
and the skin, it is necessary to apply a solvent for the adhesive
in order to remove the device or appliance from the skin. For
example, when such device or appliance is made of silicone rubber
and a silicone resin is utilized as the medical adhesive, it is
conventional to use V.M. & P. naphthas or fluorocarbons as
solvents therefor. The V.M. & P. naphthas are very harsh and
tend to chap and blister as well as dry out the living tissue to
which they are applied. The liquid fluorocarbons are expensive, and
also tend to chap and dry out the skin. The deleterious effects on
the skin which are imparted by the conventional solvents result (1)
from the irritating effect the chemicals have upon the skin, and
(2) because the solvents actually leach essential body fats and
oils from the skin and leave them dry, chapped and scaly.
Therefore, one object of this invention is to provide a solvent
composition which will effectively remove conventional medical
adhesives from skin, but is nondeleterious to the human body.
A further object of this invention is to provide a novel solvent
composition which will effectively remove medical adhesives from
skin while simultaneously treating the skin to prevent drying and
chapping.
A further object of this invention is to provide a novel solvent
composition which will effectively remove silicone resin, medical
adhesives and simultaneously treat the skin to prevent drying and
chapping while preparing the skin to tenaceously receive a
subsequent coating of silicone resin adhesive.
According to the invention, a solvent composition is provided which
is particularly suitable for removing medical adhesives from the
skin, and comprises a major effective amount of a liquid aliphatic
hydrocarbon fraction as solvent, and a minor effective skin
conditioning amount of a silicone fluid. In addition, the solvent
composition preferably contains an effective proportion of a flash
point suppressant for the liquid aliphatic hydrocarbons.
According to a preferred embodiment of this invention, the medical
adhesive solvent composition is provided which comprises a major
effective amount of an aliphatic hydrocarbon fraction which
includes from about 30 to about 70 weight percent of a fraction
consisting essentially of aliphatic C.sub.8 and C.sub.9
hydrocarbons and from about 30 to 70 weight percent of a fraction
consisting essentially of aliphatic C.sub.10 and C.sub.11
hydrocarbons; from about 15 to about 25 weight percent of flash
point suppressant; and at least about 2 weight percent of a
silicone fluid. A particularly effective combination includes equal
parts of the aliphatic C.sub.8 -C.sub.9 fraction and the C.sub.10
-C.sub.11 fraction.
The composition of the subject invention can be utilized to remove
conventional medical adhesives from the skin, and from other
surfaces such as the skin contacting surfaces of prosthetic devices
and body appliances. It is herein noted that the term "body
appliance" as used in the scope of this invention includes any
prosthetic device or body appliance which is attached to the body
by medical adhesive compositions.
Furthermore, the composition of the subject invention is
particularly effective for both removing silicone resin medical
adhesive compositions from the skin, and preparing the skin for
applications of such silicone resin medical adhesive compositions.
The liquid aliphatic hydrocarbon solvent fraction is non-toxic and
is not readily absorbed through human skin but yet functions to
dissolve conventional medical adhesive compositions such as
silicone resin adhesive compositions. In addition, the silicone
fluid component functions not only to replace body fats and oils
which have been leached by the solvent component, but also
functions to prepare the skin to tenaceously receive a subsequent
application of silicone resin.
The liquid aliphatic hydrocarbon fraction used in the solvent
composition of this invention can have aliphatic components
therewithin, containing from about 6 to about 15 carbon atoms. To
avoid volatility extremes and yet utilize extremely effective
solvent components for a medical adhesive, it is generally
preferred that the liquid aliphatic hydrocarbons consist
essentially of from C.sub.8 to C.sub.11 straight and/or branched
chain molecules. While some unsaturation can be present in the
molecules, the preferred fractions contain a majority of paraffinic
components. The percentage of the individual components can be
varied as desired within the scope of this invention. For example,
the aliphatic solvent fraction can comprise a majority of C.sub.8
's, C.sub.9 's, C.sub.10 's, or C.sub.11 's or various combinations
thereof.
The most preferred liquid aliphatic hydrocarbon fraction which can
be used in the solvent composition of this invention includes from
about 30 to 70 weight percent of a first fraction of aliphatic
C.sub.8 -C.sub.9 (C.sub.8 's and/or C.sub.9 's) hydrocarbons
combined with from about 30 to about 70 weight percent of a second
fraction of aliphatic C.sub.10 -C.sub.11 (C.sub.10 's and/or
C.sub.11 's) hydrocarbons. This fraction in combination with the
other ingredients of the subject composition has been found to be
particularly effective for removing medical adhesives, such as
silicone resins and yet not impart deleterious effects to the skin.
Generally, said first fraction will have a boiling range at 760 mm
Hg within the range of from 200.degree.-260.degree.F, and said
second fraction will have a boiling range at 760 mm Hg within the
range of from 300.degree. to 350.degree. F.
The silicone fluid which can be used in the scope of this invention
includes any of the liquid organosiloxane polymers which are
nondeleterious to human skin, for example, the methyl or phenyl
polysiloxanes. The organisiloxane polymers which can be used in the
composition of this invention have a wide range of viscosities of
less than 1 (about 0.65) to several thousand centistokes. It is
generally preferable to utilize an organosiloxane which has a
viscosity in the range of from about 10 to about 100 centistokes.
The silicone fluid is generally contained within the composition of
the subject invention in amounts of at least about 2 weight percent
thereof, and is most preferably contained in the composition of
this invention within the range of about 2 to about 4 weight
percent. Greater amounts (for example 10 weight percent) can be
used if desired; however, it has been found that a silicone fluid
content of from 2 to 4 weight percent is sufficient for most
uses.
As described above, the silicone fluid functions in cooperation
with the liquid aliphatic hydrocarbon component in the solvent
composition of this invention. When the solvent composition of the
subject invention is applied to an adhesive coating on animal skin,
and particularly human skin, the silicone fluid readily coats the
living tissue and functions to immediately replace body fats and
oils which are leached therefrom by the action of the solvent.
Thus, the silicone fluid efficiently coats the skin and combines
with the skin to thereby prevent chapping and irritation due to
loss of body fats and oils. This residue or coating of the silicone
resin upon the skin which results from the application of the
solvent composition of this invention thereto, tenaceously adheres
to the skin and will not be removed by the application of mild
soaps or detergents when removing the solvent-adhesive residue or
when washing the skin after the solvent-adhesive residue has been
wiped away.
The residue or coating which remains on the skin after application
of the solvent composition of this invention imparts a special
affinity to the skin for subsequent amounts of the silicone resin.
Thus, it has been found that when the solvent composition of the
subject invention is used to remove the silicone resin, subsequent
applications of the silicone resin when re-applying the prosthetic
device or body applicance will be received more uniformly on the
skin and form a more efficient seal between the skin and the device
or appliance than when conventional solvents are initially
utilized.
In addition to the liquid aliphatic hydrocarbons and the silicone
fluid components of the subject invention, a flash point
suppressant or retarder is preferably added thereto. Any suitable
flash point suppressant which is nondeleterious to the human body
can be used in the scope of this invention. The preferred flash
point suppressants are the halogenated lower alkyl hydrocarbons
(about 1 to about 5 carbon atoms), such as for example,
trichloroethane, tetrachlorodifluoroethane,
trichloromonofluoromethane, trichlorotrifluoroethane, mixtures
thereof and the like. The flash point suppressant is added to the
solvent composition of this invention generally in amounts ranging
from about 15 weight percent to about 25 weight percent thereof,
depending upon the volatility of the particular liquid aliphatic
hydrocarbon fraction used in said composition. Most preferably, the
flash point suppressant is added in amounts of from about 18 to
about 20 weight percent of the total composition. Generally, the
flashpoint of the resulting composition then will be no less than
80.degree. F as determined by ASTM D-56, and will generally be at
least 100.degree. F or more.
The components of the solvent composition of the subject invention
can be admixed in any suitable manner. For example, it is
convenient to add the silicone fluid and the flash point
suppressant to the liquid aliphatic hydrocarbon and mix until a
generally uniform composition is obtained.
The following example is given to further illustrate the scope of
this invention and is not intended to limit the scope thereof:
EXAMPLE
A solvent composition of the subject invention was made by admixing
40 parts by weight of a first liquid aliphatic hydrocarbon mixture
consisting essentially of C.sub. 8 and C.sub.9 hydrocarbons (a
mixture sold under the trademark of SOLTROL 10 by Phillips
Petroleum Co.) and haVing the characteristics as set forth in Table
I below, with 40 parts by weight of a second liquid aliphatic
hydrocarbon fraction consisting essentially of C.sub.10 and
C.sub.11 hydrocarbons (a mixture sold under the trademark of
SOLTROL 100 by Phillips Petroleum Co.) and having the
characteristics as set forth in Table II below.
TABLE I
__________________________________________________________________________
Property Typical Test Method
__________________________________________________________________________
Distillation, rec., .degree.F at 760 mm ASTM D-86 IBP 202 10% 209
50% 217 90% 227 DP 245 API Gravity, 60.degree.F 69.5 ASTM D-287
Specific Gravity, 60/60.degree.F 0.7040 ASTM D-1298 Density at 60
F, lb/gal 5.860 ASTM D-1250 Vapor Pressure, psia at 100.degree.F
1.9 ASTM D-323 Saybolt Color +30 ASTM D-156 Sulfur Content, wt %
0.0033 ASTM D-1266 Acidity of Distillation Residue neutral ASTM
D-1093 Copper Corrosion, 2 hrs at 212.degree.F 1 ASTM D-130 Doctor
Test negative ASTM D-484 Kauri-Butanol Value 28.2 ASTM D-1133
Nonvolatile Matter, g/100ml none ASTM D-1353 kinematic Viscosity,
cs at 32.degree.F 0.976 ASTM D-445 cs at 100.degree.F 0.633
__________________________________________________________________________
TABLE II
__________________________________________________________________________
Property Typical Test Method
__________________________________________________________________________
Distillation, evap., .degree.F at 760 mm ASTM D-86 IBP 315 10% 317
50% 327 90% 331 95% 335 DP 343 API Gravity at 60.degree.F 58.7 ASTM
D-287 Specific Gravity, 60/60.degree.F 0.744 ASTM D-1298
20/4.degree.C 0.740 Westphal Balance Density at 60.degree.F, lb/gal
6.19 ASTM D-1250 Flash Point, TCT, .degree.F. 105 ASTM D-56 Color,
Saybolt +30 ASTM D-156 Corrosion, Copper Strip, 3 hrs at
212.degree.F 1 ASTM D-130 Acidity of Distillation Residue neutral
ASTM D-1093 Aniline Point, .degree.F 179 ASTM D-1012
__________________________________________________________________________
Next, 18 parts by weight by trichloroethane and 2 parts by weight
of silicone fluid (a silicone fluid sold under the trademark of DC
200, by Dow-Corning and having from 10 to 100 centistokes
viscosity) was added to the 80 parts by weight of the liquid
aliphatic hydrocarbons to form the medical solvent composition of
the subject invention.
This medical solvent composition was used to remove a medical
adhesive (a silicone resin medical adhesive sold under the
trademark of MEDICAL ADHESIVE "B" by Dow-Corning Medical Products
Division). The medical adhesive was used in attaching to a human
male a prosthetic device for the handling of urinary incontinence.
This prosthetic device basically comprised a knit sheath
impreganted with silicone rubber and is fully disclosed in my
copending patent application Ser. No. 008,819, filed Feb. 5, 1971.
The solvent was used to remove the device numerous times over a
period of several months. In each instance, the solvent composition
was applied during the removal operation and thereafter the skin
area which was contacted by the solvent composition was washed with
mild soap and water and the solvent residue containing the
dissolved adhesive was flushed away. A layer of silicone fluid
remained on the skin. When it was desired to reapply the prosthetic
device, the silicone resin medical adhesive was applied over the
skin which carried the silicone fluid coating, and the prosthetic
device then applied thereto. During this several months period, no
skin irritation whatsoever was observed and furthermore, the
silicone resin adhesive was found to very effectively adhere to the
treated area in an improved manner than when conventional solvents
such as V.M. & P. naphthas are used to remove the medical
adhesive.
While this invention has been described in relation to its
preferred embodiments, it is to be understood that various
modifications will be apparent to one skilled in the art from a
reading of this specification, and it is intended to cover such
modifications as fall within the scope of the appended claims.
* * * * *